Summary We have evaluated the feasibility, toxicity, and tumour response of concurrent whole-brain radiotherapy (WBRT) and chemotherapy with cisplatin, vindesine and mitomycin in the treatment of 33 patients with brain metastasis from non-small-cell lung cancer (NSCLC). The imaging response demonstrated that 25 patients (75.8%) responded to brain lesions, including five complete responders, and the response rate to primary lesion was 18%. The treatment improved at least one grade of performance status in 30% and of neurological functions in 55% of the patients. The major toxicity was leucopenia (2 grade 3, 84.4%). Median survival was 9.7 months and the 1-year survival rate was 40%. Concurrent WBRT and chemotherapy can be safely administered to patients with brain metastasis from NSCLC, with a remarkable response rate, improvement of neurological functions and encouraging survival duration.
Resection of single-brain metastasis and post-operative wholebrain radiotherapy (WBRT) can improve survival compared with treatment using WBRT alone (Horton, 1971) . For this reason, surgical resection has become part of the standard management of appropriately selected patients with inactive extracranial disease (Kornblith et al, 1985; Patchell et al, 1990; Vecht et al, 1993) .
In most instances, brain metastases are multiple and occur in the presence of metastasis to other organs (Sundaresan et al, 1993) . WBRT rather than surgery has been used as the primary treatment modality in the management of brain metastasis. More than 75% of patients benefit symptomatically from WRBT for a short time, and median survival varies from 15 to 18 weeks (Lee et al, 1989) .
As most patients have disseminated disease, more attention should be paid to the use of systemic chemotherapy in brain metastases, which could offer control of cranial as well as extracranial disease. Chemotherapy for brain metastases has been considered ineffective because the drugs do not penetrate the intact blood-brain barrier (BBB). However, some reports have demonstrated a breakdown of the BBB in metastatic brain tumours, which diminishes the restrictions in the transport of drugs normally exerted (Workman, 1986; Greig, 1989) . Several studies have reported a higher concentration of drugs in brain tumours than in the brain or an increased tumour-plasma ratio (Stewart et al, 1979 (Stewart et al, , 1983 (Stewart et al, , 1984 .
The mitomycin, vindesine and cisplatin (MVP) regimen has demonstrated neurological improvement and good response in patients with brain metastasis from NSCLC in Japan (Kasamatsu et al, 1990; Yamamoto and Furuse et al, 1995) .
The combination of chemotherapy and radiotherapy could increase cytotoxicity by interfering with cells' ability to repair injury caused by the other treatment. In this manner, combined treatments could result in additive or supra-additive cytotoxic effects. Also, there are laboratory data to suggest that cisplatin increases radiation sensitivity (Kornblith et al, 1985) .
The objective of this study is to evaluate the technical feasibility, toxicity and tumour response of concurrent WBRT and MVP in the treatment of patients with brain metastasis from NSCLC.
PATIENTS AND METHODS Eligibility
Patients had to fulfil all the following criteria to be entered in the study: a histologically or cytologically proven diagnosis of NSCLC; stage IV with brain metastasis; an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of < 3; age less than 75 years; no massive pleural effusion; no severe pain due to bone metastasis; adequate haematological [Hb > 9.5 g dl-', white blood cell count . 4000 gl-', platelet (PLT) count 2 100 000 g 1-'], hepatic (serum bilirubin < 2.0 mg dl'; ALT, AST and alkaline phosphatase < double upper limit of normal) and renal (serum creatinine < 1.1 mg dl-') functions; no active concomitant malignancies; no previous treatment of primary or brain lesion; and no consciousness disturbance or systemic convulsion. Informed consent was obtained from all patients.
Treatment
Chemotherapy consisted of vindesine (3 mg m-2 on days 1, 8, 29 and 39), cisplatin (100 mg m-2 on days 1 and 29) and mitomycin (1980) . Toxicity (8 mg m-2 on days 1 and 29). The doses were modified on the basis of blood counts and renal functions on the day of therapy (Furuse et al, 1995) . On day 2 of chemotherapy, WBRT was administered using a linear accelerator for 5 weeks at a dose of 2 Gy given 20 times. The dose was given in five fractions per week.
Response
Treatment response was evaluated through periodic reassessment of PS and neurological function (FN) as described by Borgelt (1980) and the Radiation Therapy Oncology Group (Table 1) . Patients were evaluated before treatment-weekly for the first 4 weeks, monthly for 2 or more months and every 3 months thereafter.
Response to brain lesions was evaluated by contrast-enhanced brain computerized tomography (CT) before treatment and 8 weeks after treatment. If the findings showed partial or complete response after WBRT, these responses were reconfirmed after 4
Patients were evaluated every week during WBRT and chemotherapy. Toxicity was rated according to WHO criteria (1979) .
Statistical methods
Survival was calculated on the basis of the period from the start of treatment to death or the last follow-up. The survival curve was calculated by the method of Kaplan and Meier.
Available treatment variables, which in some other series proved to have influence on the treatment of NSCLC, were investigated for any possible relationship to the probability of survival as a result of the treatment of NSCLC, first in univariate analysis and subsequently by application of a multiple regression model. The univariate was based on 2 x 2 tables, and differences were tested by use of the chi-square test. A P-value of 0.05 was regarded as significant.
Differences in survival duration were compared using a twosided log-rank test (Mantel, 1966) . To adjust for any confounding variables and to assess the relative importance of different prognostic variables for survival, Cox's proportional hazards model (1972) was used.
RESULTS

Distribution of prognostic factors
From April 1991 to August 1994, 33 patients were entered into this study. The distribution of the patients' prognostic factors is given in Table 2 . The estimated median survival of all patients from the start of treatment to death or the last follow-up was 229 days, with 30% being alive I year after treatment (Figure 1) . The effects of a number of potential prognostic factors on survival was examined initially using univariate analysis (Table 1) . Patients with a single metastatic lesion survived longer than those with multiple lesions (P = 0.0288). Other prognostic factors had no significant effect on survival.
Stepwise multiple regression analysis was carried out to determine the prognostic factors, except for histology, significantly influencing survival. The only statistically significant prognostic factor found to be associated with survival was the number of brain metastatic lesions (P = 0.0339).
Toxicity
In total, 63 courses of MVP were given. Twenty-six patients received two courses, three patients three courses and five only one course. The toxicities observed during the entire treatment of 33 patients are listed in (Boogerd et al, 1992) describe response rates in the brain similar to those in other organ sites. Kasamatsu et al (1990) in Japan reported on a study in which five patients with NSCLC and brain metastases were treated with a mitomycin, vindesine and cisplatin regimen. Of the five patients, three had a PR for brain lesion and five showed neurological improvement. Their survival time ranged from 6 to 8 months. Also, Yamamoto et al (1993) reported that 22 NSCLC patients associated with brain metastasis were treated with chemotherapy regimens including cisplatin, with three patients having a CR and two a PR for brain lesions.
In patients with malignant gliomas, adjuvant chemotherapy in addition to WBRT increased the number of long-term survivors 200 400 600 800 1000 (Walker et al, 1978) . Hidalgo et al (1987) reported, in his series, Days that five patients with NSCLC and brain metastases were treated Overall survival of 33 eligible patients treated with WBRT and MVP with weekly cisplatin (40-60 mg m-2) during WBRT (50 Gy over 5 weeks). Three patients had a CR and two a PR to the treatment, and four were alive more than 6 months later. Also, Lange et al (1987) reported that 27 patients with NSCLC and brain metastases e treatment. The median duration of response for brain were treated with ifsofamide (daily for 5 days at 2 g m-2) and was 223 days (range 43-892 days). In 33 primary lung BCNU (at 30 mg m-2 on days 1,3 and 5) and radiotherapy was six (18%) had a PR after WBRT and MVP.
given simultaneously. Of the 27, seven patients had a CR and 12 a PR. The mean time of survival was 9.5 months for patients with NSCLC. In an uncontrolled study of patients with brain metastases from solid tumours, concurrent radiotherapy and chemotherapy tion of performance status and neurological function appeared to increase the median survival, although no information ing to response is shown in Figure 1 . Among the 33 was provided regarding the extent of extracranial metastatic s, ten (30%) improved in more than one category of PS, and disease or other prognostic factors. .5%) improved in more than one score of FN. However, In our study of concurrent WBRT and chemotherapy with the 33 patients, six (18%) worsened in at least one category cisplatin, vindesine and mitomycin for NSCLC with brain metaind two (6%) worsened in at least one score of FN. At the stasis, the response rate of the brain lesion to treatment was follow-up of 8.0 months (range 1.4-29.7 months), five 75.8% (including five patients with CRs), and the response rate of s(15%) had died of local recurrence of brain lesions. Of the the primary lesion to treatment was 18%. Also, the treatment ients who had neurological dysfunction before the treatimproved at least one grade of performance status in 30% and at 14 had (61%) died of their other metastatic lesions before least one grade of neurological functions in approximately 55% of nces of brain lesions, three had died of local recurrence of the patients. Median survival was 8 months and the 1-year survival sions and six were alive. rate was 40%. Median survival duration and 1-year survival rate, in our study, were better than the median survival durations (3-6 ial months) and 1-year survival rates (approximately 20%) in the previously mentioned WBRT-alone trials (Chu and Hilaris, 1961 ; median follow-up time of 8.0 months (range 1. 4-29.7 Order et al, 1968; West and Maor, 1980) , although our study was ,), the median survival time in these 33 patients was 8 uncontrolled and had a bias for patient selection. and the 1-year survival rate was 40% (Figure 2 ). Of these The major toxicity in this pilot study was leucopenia. Late toxients, 26 died because of cancer and seven remained alive city of concurrent WBRT and chemotherapy are becoming more .3, 13.2, 13.3, 14.5, 14.9 and 29.7 months after the treatimportant with the longer survival of patients with metastatic )f these 26 patients, 21 had no local brain recurrence.
disease (DeAngelis et al, 1989 We have shown the ability to safely administer concurrent orted in 31-49% of patients. Thus, in spite of WBRT, up to WBRT and MVP chemotherapy for patients with NSCLC and the patients eventually developed recurrence of their brain brain metastasis. There is an excellent imaging response rate to before death due to other metastases.
brain tumours, associated with improvement of neurological func-:nt reports on chemotherapy for patients with brain metastion and notable survival rates at a median survival duration and at om small-cell lung cancer (Kristjansen and Hansen, 1988;  1 year after treatment. To evaluate the true benefit and the best use al, 1989 ; Twelves et al, 1990; Postmus et al, 1995) , adeno-(accounting for quality of life and toxicity) of this treatment ima of the lung (Kantarjian et al, 1984) , gestational choriomodality, we are conducting a prospective multicentre randomized ima (Weed and Hammond, 1980; Sen et al, 1987) , germ cell study comparing WBRT with or without concurrent chemotherapy ancies (Newlands, 1985; Allen et al, 1987) and breast for patients with NSCLC and brain metastasis.
